{"url_path":"/sec/anvs/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 ****Submission","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-075198-index.html","accession_number":"0001104659-26-075198","cik":"0001477845","ticker":"ANVS","issuer_name":"Annovis Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-075198-index.html","primary_entity_key":"0001477845","primary_entity_name":"Annovis Bio, Inc."},"word_count":499,"has_tables":true,"body_markdown":"**Item\n5.07****Submission\nof Matters to a Vote of Security Holders.**\n\n \n\nOn June 17, 2026,\nAnnovis Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually.\nAt the Annual Meeting, five proposals were submitted to the Company’s stockholders and all matters voted upon were approved with\nthe required votes. The proposals are outlined below and further described in the Company’s definitive proxy statement filed with\nthe U.S. Securities and Exchange Commission on April 30, 2026.\n\n \n\nAt the Annual Meeting,\na total of 21,705,113 shares of the Company’s common stock, or 62.65% of the common stock outstanding as of April 28, 2026,\nthe record date for the Annual Meeting, were represented virtually or by proxy.\n\n \n\nThe following is a brief\ndescription of the final voting results for each of the five proposals submitted at the Annual Meeting on June 17, 2026:\n\n \n\n**1.\nElection of Directors**\n\n \n\nAll of the following\nfive nominees were elected to the Company’s Board of Directors, in accordance with the voting results listed below, to serve for\na term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.\n\n \n\nNominees: \nFor \nWithold \nBroker Non-Vote\n\nMichael Hoffman \n\n8,604,453\n \n\n550,520\n \n\n12,550,140\n\nMaria Maccecchini \n8,588,620 \n\n566,353\n \n\n12,550,140\n\nClaudine Bruck \n\n8,666,606\n \n\n488,367\n \n12,550,140\n\nReid McCarthy \n\n8,591,131\n \n563,842 \n12,550,140\n\nMark White \n\n8,204,328\n \n\n950,645\n \n12,550,140\n\n \n\n**2.\nRatification of the Company’s Independent Auditors**\n\n \n\nThe ratification of the appointment of Ernst &\nYoung LLP was approved by stockholders by the following vote:\n\n \n\nFor \nAgainst \nAbstain\n\n20,634,176\n \n\n568,155\n \n\n502,782\n\n \n\n**3.****Amendment to the Annovis Bio, Inc. 2019 Equity Incentive\nPlan**\n\n \n\nThe\namendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to increase the number\nof shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded\nin any one year from 400,000 to 600,000 shares, was approved by stockholders by the following vote:\n\n \n\nFor \nAgainst \nAbstain\n \n**Broker Non-Vote**\n\n8,089,891\n \n\n899,671\n \n165,409\n \n12,550,142\n\n \n\n**4.****ADVISORY (NON-BINDING) VOTE ON THE COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE\nOFFICERS**\n\n \n\nThe\ncompensation of the Company’s named executive officers was approved by the stockholders\non an advisory (non-binding basis), by the following vote:\n\n \n\n**Broker Non-Vote**\n\n \n\nFor \nAgainst \nAbstain\n \n**Broker Non-Vote**\n\n8,067,931\n \n\n901,342\n \n\n185,701\n\n \n12,550,139\n\n \n\n**5.****ADVISORY (NON-BINDING) VOTE ON THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON\nCOMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS**\n\n \n\n“**TWO\nYEARS**” as the preferred frequency on the compensation of the Company’s named executive officers was approved by\nstockholders on an advisory (non-binding basis), by the following vote:\n\n \n\n1-Year \n2-Years\n \n**3-Years** \nAbstain\n \n**Broker Non-Vote**\n\n2,526,008\n \n\n5,390,514\n\n \n1,086,528 \n\n151,922\n\n \n12,550,141\n\n \n\n(d)\n In light of this vote, and consistent with the recommendation of the Board of Directors, the Company has determined that\nit will include a stockholder advisory vote on executive compensation in its proxy materials every two years until the next required advisory\nvote on the frequency of such votes occurs, or until the Board of Directors otherwise determines a different frequency for such votes."}